Use of antipsychotic medications in Australia between July 1995 and December 2001

References

• Murray R R, Schooler N R, (chairs). Novel antipsychotic use in schizophrenia (academic highlights). Journal of Clinical Psychiatry 2000; 61: 223–232
   PubMedGoogle Scholar
• Meltzer H Y. Outcome in schizophrenia: beyond symptom reduction. Journal of Clinical Psychiatry 1999; 60(Suppl. 3)3–7
   PubMed Web of Science ®Google Scholar
• Keks N, Mazumdar P, Steele K. The new antipsychotics: how much better are they?. Australian Family Physician 2000; 29: 445–450
   PubMedGoogle Scholar
• Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45: 789–796
   PubMed Web of Science ®Google Scholar
• Sharif Z A, Raza A, Ratakonda S S. Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. Journal of Clinical Psychiatry 2000; 61: 498–504
   PubMed Web of Science ®Google Scholar
• The Expert Consensus Guideline Series Treatment of schizophrenia. Journal of Clinical Psychiatry 1999; 60(Suppl. 11)1–80
   Google Scholar
• Geddes J. Prevention of relapse in schizophrenia. New England Journal of Medicine 2002; 346: 56–58
   PubMed Web of Science ®Google Scholar
• Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. European Psychiatry 2000; 15: 220–226
   PubMed Web of Science ®Google Scholar
• Galletly C. Prescribing of psychotropic drugs in an acute inpatient unit. Australian and New Zealand Journal of Psychiatry 1999; 33: 281–282
   PubMed Web of Science ®Google Scholar
• Lambert T. Pharmacology of depot antipsychotics. Directions in psychiatry. Eli Lilly, Sydney 1999; 16–17, Forum 6
   Google Scholar
• Keks N A, Altson K, Hope J, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Australian and New Zealand Journal of Psychiatry 1999; 33: 896–901
   PubMed Web of Science ®Google Scholar
• Lambert T, Singh B. Psychotropic prescribing in community mental health clinics. International Journal of Neuropsychopharmacology 2000; 3: S123, 22nd CINP Brussels
   Google Scholar
• Jablensky A, McGrath J, Herrman H, et al. Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Australian and New Zealand Journal of Psychiatry 2000; 34: 221–236
   PubMed Web of Science ®Google Scholar
• World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2nd edn. WHO, Oslo 1998
   Google Scholar
• Mant A, Whicker S D, McManus P, Birkett D J, Edmonds D, Dumbrell D. Benzodiazepine utilization in Australia: report from a new pharmacoepidemiological database. Australian Journal of Public Health 1993; 17: 345–349
   PubMedGoogle Scholar
• Commonwealth Department of Health and Aged Care. Australian statistics on medicines, 1998. Department of Health and Aged Care, Canberra 1999
   Google Scholar
• McManus P, Primrose J G, Henry D A, Birkett D J, Lindner J, Day R O. Pattern of non-steroidal anti-inflammatory drug use in Australia: a report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Medical Journal of Australia 1996; 164: 589–592
   PubMed Web of Science ®Google Scholar
• McManus P, Hammond M L, Whicker S D, Primrose J G, Mant A, Fairall S R. Antibiotic use in the Australian community. Medical Journal of Australia 1997; 167: 124–127
   PubMed Web of Science ®Google Scholar
• McManus P, Mant A, Mitchell P B, Montgomery W S, Marley J, Auland M E. Recent trends in the use of antidepressant drugs in Australia. Medical Journal of Australia 2000; 173: 458–461
   PubMed Web of Science ®Google Scholar
• Commonwealth Department of Health and Aged Care. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners, May 2001. Department of Health and Aged Care, Canberra 2001
   Google Scholar
• World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC. Index with DDDs, 2001. WHO, Oslo 2000
   Google Scholar
• Australian Bureau of Statistics. Australian Demographic Statistics. ABS, Canberra 2001, Cat, 3101.0. (1995–2001)
   Google Scholar
• Weiden P J, Aquila R, Dalheim L, Standard J M. Switching antipsychotic medications. Journal of Clinical Psychiatry 1997; 58(Suppl. 10)63–72
   PubMed Web of Science ®Google Scholar
• Glick I D, Murray S R, Vasudevan P, Marder S R, Hu R J. Treatment with atypical antipsychotics: new indications and new populations. Journal of Psychiatric Research 2001; 35: 187–191
   PubMed Web of Science ®Google Scholar
• Parker G, Malhi G. Are atypical antipsychotic drugs also atypical antidepressants?. Australian and New Zealand Journal of Psychiatry 2001; 35: 631–638
   PubMed Web of Science ®Google Scholar
• Snowdon J. A follow-up survey of psychotropic drug use in Sydney nursing homes. Medical Journal of Australia 1999; 170: 299–301
   PubMed Web of Science ®Google Scholar
• Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. European Archives of Psychiatry and Clinical Neuroscience 2000; 250: 274–285
   PubMed Web of Science ®Google Scholar
• Shen W W. The need for depot atypical antipsychotics in the US. Psychiatric Services 1998; 49: 727
   PubMed Web of Science ®Google Scholar
• Adams C E, Fenton M KP, Quraishi S, David A S. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 2001; 179: 290–299
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. Melleril (thioridazine)–important changes to product information. Novartis, New Jersey September, 2000
   Google Scholar
• Tran P V, Hamilton S H, Kuntz A J, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 1997; 17: 407–418
   PubMed Web of Science ®Google Scholar
• Conley R R, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2001; 158: 765–774
   PubMed Web of Science ®Google Scholar
• Thomas C S, Lewis S. Which atypical antipsychotic?. British Journal of Psychiatry 1998; 172: 106–109
   PubMed Web of Science ®Google Scholar
• Stahl S M. Selecting an atypical antipsychotic by combining clinical experiences with guidelines from clinical trials. Journal of Clinical Psychiatry 1999; 60(Suppl. 10)31–41
   PubMed Web of Science ®Google Scholar
• Ganguli R. Weight gain associated with antipsychotic drugs. Journal of Clinical Psychiatry 1999; 60(Suppl. 21)20–24
   PubMed Web of Science ®Google Scholar
• Allison D B, Mentore J L, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156: 1686–1696
   PubMed Web of Science ®Google Scholar
• Goldstein L E, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438–443
   PubMed Web of Science ®Google Scholar
• Lewis M, McCrone P, Frangou S. Service use and costs of treating schizophrenia with atypical antipsychotics. Journal of Clinical Psychiatry 2001; 62: 749–756
   PubMed Web of Science ®Google Scholar
• Therapeutic Guidelines. Psychotropic drug guidelines, 4th edn. Therapeutic Guidelines, Melbourne 2000
   Google Scholar
• Carpenter W T, Buchanan R W, Kirkpatrick B, Lann H D, Breier A F, Summerfelt A T. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. American Journal of Psychiatry 1999; 156: 412–418
   PubMed Web of Science ®Google Scholar
• Kendrick T. The newer, ‘atypical’ antipsychotic drugs–their development and current therapeutic use. British Journal of General Practice 1999; 49: 745–749
   PubMed Web of Science ®Google Scholar
• Keks N, Burrows G D. Psychotropic drug prescribing: first the good news. Medical Journal of Australia 1999; 170: 293–294
   PubMed Web of Science ®Google Scholar